Skip to main content
SpringerLink
Log in
Book cover

Inflammation and Lung Cancer pp 95–136Cite as

Inflammation and Lung Cancer: Prevention

  • Chapter
  • First Online:

  • 1204 Accesses

Abstract

In this chapter, the authors focus on preclinical animal modeling including the basic science connecting inflammation and lung cancer chemoprevention, preclinical testing in animal models, clinical trials, and future directions. Animal models consistently demonstrate that certain inflammatory pathways are clearly important in lung carcinogenesis. Many of these pathways, such as NRF2, PPARγ, and NFκB, are linked to multiple cancer stages (i.e., initiation, promotion, progression, and metastasis) and some (e.g., NRF2, PPARγ) are linked to both pro- and anti-inflammatory pathways depending on the stage. This emphasizes the importance of a stage-dependent approach to therapy. In addition, these early animal studies often identify systemic problems (e.g., cardiac effects of COX-2-specific inhibitors). Although no Phase III trials with lung cancer as the primary endpoint have generated the robust data that would be needed to make recommendations for chemoprevention, both low-dose aspirin and inhaled corticosteroids are of interest for further study. Iloprost has significant preclinical and Phase II data to support further investigation.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Reference

  1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29

    Article  PubMed  Google Scholar 

  2. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365(5):395–409

    Article  PubMed  Google Scholar 

  3. Sporn MB (1976) Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 36(7 Pt 2):2699–2702

    CAS  PubMed  Google Scholar 

  4. Johnson BE (1998) Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst 90(18):1335–1345

    Article  CAS  PubMed  Google Scholar 

  5. Jonsson S, Thorsteinsdottir U, Gudbjartsson DF, Jonsson HH, Kristjansson K, Arnason S, Gudnason V, Isaksson HJ, Hallgrimsson J, Gulcher JR, Amundadottir LT, Kong A, Stefansson K (2004) Familial risk of lung carcinoma in the Icelandic population. JAMA 292(24):2977–2983

    Article  CAS  PubMed  Google Scholar 

  6. Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, Hsieh LJ, Begg CB (2003) Variations in lung cancer risk among smokers. J Natl Cancer Inst 95(6):470–478

    Article  PubMed  Google Scholar 

  7. Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers J, Vu K, Haney J, Kennedy TC, Hirsch FR, Miller Y, Franklin WA, Herman JG, Baylin SB, Bunn PA, Byers T (2006) Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 66(6):3338–3344

    Article  CAS  PubMed  Google Scholar 

  8. International Agency for Research on Cancer (2009) IARC monographs on the evaluation of carcinogenic risks to humans. Volume 100C: Arsenic, metals, fibres, and dusts. [cited 2014 May 27]. http://monographs.iarc.fr/ENG/Monographs/vol100C/mono100C.pdf. Accessed 01 May 2014

  9. Spitz MR, Etzel CJ, Dong Q, Amos CI, Wei Q, Wu X, Hong WK (2008) An expanded risk prediction model for lung cancer. Cancer Prev Res (Phila) 1(4):250–254

    Article  Google Scholar 

  10. Prindiville SA, Byers T, Hirsch FR, Franklin WA, Miller YE, Vu KO, Wolf HJ, Baron AE, Shroyer KR, Zeng C, Kennedy TC, Bunn PA (2003) Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction. Cancer Epidemiol Biomarkers Prev 12(10):987–993

    PubMed  Google Scholar 

  11. van Boerdonk RA, Sutedja TG, Snijders PJ, Reinen E, Wilting SM, van de Wiel MA, Thunnissen FE, Duin S, Kooi C, Ylstra B, Meijer CJ, Meijer GA, Grunberg K, Daniels JM, Postmus PE, Smit EF, Heideman DA (2011) DNA copy number alterations in endobronchial squamous metaplastic lesions predict lung cancer. Am J Respir Crit Care Med 184(8):948–956

    Article  PubMed  CAS  Google Scholar 

  12. Licchesi JD, Westra WH, Hooker CM, Herman JG (2008) Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung. Clin Cancer Res 14(9):2570–2578

    Article  CAS  PubMed  Google Scholar 

  13. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674

    Article  CAS  PubMed  Google Scholar 

  14. Cancer Genome Atlas Research Network (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489(7417):519–525

    Article  CAS  Google Scholar 

  15. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, Stojanov P, Cibulskis K, Choi K, de Waal L, Sharifnia T, Brooks A, Greulich H, Banerji S, Zander T, Seidel D, Leenders F, Ansen S, Ludwig C, Engel-Riedel W, Stoelben E, Wolf J, Goparju C, Thompson K, Winckler W, Kwiatkowski D, Johnson BE, Janne PA, Miller VA, Pao W, Travis WD, Pass HI, Gabriel SB, Lander ES, Thomas RK, Garraway LA, Getz G, Meyerson M (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150(6):1107–1120

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Coussens LM, Zitvogel L, Palucka AK (2013) Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339(6117):286–291

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE, Lung G (2005) Health Study Research, The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 142(4):233–239

    Article  PubMed  Google Scholar 

  18. Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN, McAfee T, Peto R (2013) 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med 368(4):341–350

    Article  CAS  PubMed  Google Scholar 

  19. Tong L, Spitz MR, Fueger JJ, Amos CA (1996) Lung carcinoma in former smokers. Cancer 78(5):1004–1010

    Article  CAS  PubMed  Google Scholar 

  20. Halpern MT, Gillespie BW, Warner KE (1993) Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst 85(6):457–464

    Article  CAS  PubMed  Google Scholar 

  21. Stead LF, Lancaster T (2005) Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev (2):CD001007

    Google Scholar 

  22. U.S. Surgeon General Report (2010) How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease. A report of the surgeon general, 2010, Centers for Disease Control and Prevention (US), National Center for Chronic Disease Prevention and Health Promotion (US), Office on Smoking and Health (US). Atlanta, GA

    Google Scholar 

  23. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, Belanger C, LaMotte F, Gaziano JM, Ridker PM, Willett W, Peto R (1996) Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334(18):1145–1149

    Article  CAS  PubMed  Google Scholar 

  24. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL Jr, Valanis B, Williams JH Jr, Barnhart S, Cherniack MG, Brodkin CA, Hammar S (1996) Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 88(21):1550–1559

    Article  CAS  PubMed  Google Scholar 

  25. Bauer AK, Malkinson AM, Kleeberger SR (2004) Susceptibility to neoplastic and non-neoplastic pulmonary diseases in mice: genetic similarities. Am J Physiol Lung Cell Mol Physiol 287(4):L685–L703

    Article  CAS  PubMed  Google Scholar 

  26. Malkinson AM (2005) Role of inflammation in mouse lung tumorigenesis: a review. Exp Lung Res 31(1):57–82

    Article  CAS  PubMed  Google Scholar 

  27. Schottenfeld D, Beebe-Dimmer J (2006) Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 56(2):69–83

    Article  PubMed  Google Scholar 

  28. Klaunig JE, Kamendulis LM (2008) Chemical carcinogens In: Klaassen CD Casarett and Doull’s toxicology: the basic science of poisons. McGraw-Hill, USA, pp 329–380

    Google Scholar 

  29. Mayo JG (1972) Biologic characterization of the subcutaneously implanted Lewis lung tumor. Cancer Chemother Rep 2 3(1):325–330

    CAS  PubMed  Google Scholar 

  30. Wistuba II, Behrens C, Milchgrub S, Bryant D, Hung J, Minna JD, Gazdar AF (1999) Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 18(3):643–650

    Article  CAS  PubMed  Google Scholar 

  31. McCaughan F, Pipinikas CP, Janes SM, George PJ, Rabbitts PH, Dear PH (2011) Genomic evidence of pre-invasive clonal expansion, dispersal and progression in bronchial dysplasia. J Pathol 224(2):153–159

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Wang Y, Zhang Z, Yan Y, Lemon WJ, LaRegina M, Morrison C, Lubet R, You M (2004) A chemically induced model for squamous cell carcinoma of the lung in mice: histopathology and strain susceptibility. Cancer Res 64(5):1647–1654

    Article  CAS  PubMed  Google Scholar 

  33. Hudish TM, Opincariu LI, Mozer AB, Johnson MS, Cleaver TG, Malkoski SP, Merrick DT, Keith RL (2012) N-nitroso-tris-chloroethylurea induces premalignant squamous dysplasia in mice. Cancer Prev Res (Phila) 5(2):283–289

    Article  CAS  Google Scholar 

  34. Cooper EH, Splinter TA, Brown DA, Muers MF, Peake MD, Pearson SL (1985) Evaluation of a radioimmunoassay for neuron specific enolase in small cell lung cancer. Br J Cancer 52(3):333–338

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Daniely Y, Liao G, Dixon D, Linnoila RI, Lori A, Randell SH, Oren M, Jetten AM (2004) Critical role of p63 in the development of a normal esophageal and tracheobronchial epithelium. Am J Physiol Cell Physiol 287(1):C171–C181

    Article  CAS  PubMed  Google Scholar 

  36. Tago Y, Yamano S, Wei M, Kakehashi A, Kitano M, Fujioka M, Ishii N, Wanibuchi H (2013) Novel medium-term carcinogenesis model for lung squamous cell carcinoma induced by N-nitroso-tris-chloroethylurea in mice. Cancer Sci 104(12):1560–1566

    Article  CAS  PubMed  Google Scholar 

  37. Pan J, Zhang Q, Li K, Liu Q, Wang Y, You M (2013) Chemoprevention of lung squamous cell carcinoma by ginseng. Cancer Prev Res (Phila) 6(6):530–539

    Article  Google Scholar 

  38. Khan N, Afaq F, Kweon MH, Kim K, Mukhtar H (2007) Oral consumption of pomegranate fruit extract inhibits growth and progression of primary lung tumors in mice. Cancer Res 67(7):3475–3482

    Article  CAS  PubMed  Google Scholar 

  39. Fu H, Zhang J, Pan J, Zhang Q, Lu Y, Wen W, Lubet RA, Szabo E, Chen R, Wang Y, Chen DR, You M (2011) Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice. Mol Carcinog 50(12):913–921

    Article  CAS  PubMed  Google Scholar 

  40. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, Li D, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera RF, Bronson RT, Lindeman NI, Christiani DC, Lin X, Shapiro GI, Janne PA, Johnson BE, Meyerson M, Kwiatkowski DJ, Castrillon DH, Bardeesy N, Sharpless NE, Wong KK (2007) LKB1 modulates lung cancer differentiation and metastasis. Nature 448(7155):807–810

    Article  CAS  PubMed  Google Scholar 

  41. Xiao Z, Jiang Q, Willette-Brown J, Xi S, Zhu F, Burkett S, Back T, Song NY, Datla M, Sun Z, Goldszmid R, Lin F, Cohoon T, Pike K, Wu X, Schrump DS, Wong KK, Young HA, Trinchieri G, Wiltrout RH, Hu Y (2013) The pivotal role of IKKalpha in the development of spontaneous lung squamous cell carcinomas. Cancer Cell 23(4):527–540

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Ghosh S, Karin M (2002) Missing pieces in the NF-kappaB puzzle. Cell 109(Suppl):S81–S96

    Article  Google Scholar 

  43. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6(2):244–285

    Article  PubMed  PubMed Central  Google Scholar 

  44. Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H, Wang R, Ye T, Luo X, Zhang Y, Li B, Cai D, Shen L, Sun Y, Chen H (2014) ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer 84:121–126

    Article  PubMed  Google Scholar 

  45. Sun JM, Lira M, Pandya K, Choi YL, Ahn JS, Mao M, Han J, Park K, Ahn MJ, Kim J (2014) Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. Lung Cancer 83(2):259–264

    Article  PubMed  Google Scholar 

  46. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, Crowley D, Bronson RT, Jacks T (2005) Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121(6):823–835

    Article  CAS  PubMed  Google Scholar 

  47. Malkinson AM (1992) Primary lung tumors in mice: an experimentally manipulable model of human adenocarcinoma. Cancer Res 52(9 Suppl):2670s–2676s

    CAS  PubMed  Google Scholar 

  48. Malkinson AM (1998) Molecular comparison of human and mouse pulmonary adenocarcinomas. Exp Lung Res 24(4):541–555

    Article  CAS  PubMed  Google Scholar 

  49. Redente EF, Orlicky DJ, Bouchard RJ, Malkinson AM (2007) Tumor signaling to the bone marrow changes the phenotype of monocytes and pulmonary macrophages during urethane-induced primary lung tumorigenesis in A/J mice. Am J Pathol 170(2):693–708

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Gong L, Cumpian AM, Caetano MS, Ochoa CE, De la Garza MM, Lapid DJ, Mirabolfathinejad SG, Dickey BF, Zhou Q, Moghaddam SJ (2013) Promoting effect of neutrophils on lung tumorigenesis is mediated by CXCR2 and neutrophil elastase. Mol Cancer 12(1):154

    Article  PubMed Central  PubMed  Google Scholar 

  51. Rondini EA, Walters DM, Bauer AK (2010) Vanadium pentoxide induces pulmonary inflammation and tumor promotion in a strain-dependent manner. Part Fibre Toxicol 7:9

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  52. Zaynagetdinov R, Sherrill TP, Polosukhin VV, Han W, Ausborn JA, McLoed AG, McMahon FB, Gleaves LA, Degryse AL, Stathopoulos GT, Yull FE, Blackwell TS (2011) A critical role for macrophages in promotion of urethane-induced lung carcinogenesis. J Immunol 187(11):5703–5711

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  53. Proulx LI, Gaudreault M, Turmel V, Augusto LA, Castonguay A, Bissonnette EY (2005) 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone, a component of tobacco smoke, modulates mediator release from human bronchial and alveolar epithelial cells. Clin Exp Immunol 140(1):46–53

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  54. Witschi H (2000) Successful and not so successful chemoprevention of tobacco smoke-induced lung tumors. Exp Lung Res 26(8):743–755

    Article  CAS  PubMed  Google Scholar 

  55. Witschi H (2007) Tobacco smoke-induced lung cancer in animals–a challenge to toxicology (?). Int J Toxicol 26(4):339–344

    Article  CAS  PubMed  Google Scholar 

  56. Malkinson AM, Koski KM, Evans WA, Festing MF (1997) Butylated hydroxytoluene exposure is necessary to induce lung tumors in BALB mice treated with 3-methylcholanthrene. Cancer Res 57(14):2832–2834

    CAS  PubMed  Google Scholar 

  57. Sargent LM, Porter DW, Staska LM, Hubbs AF, Lowry DT, Battelli L, Siegrist KJ, Kashon ML, Mercer RR, Bauer AK, Chen BT, Salisbury JL, Frazer D, McKinney W, Andrew M, Tsuruoka S, Endo M, Fluharty KL, Castranova V, Reynolds SH (2014) Promotion of lung adenocarcinoma following inhalation exposure to multi-walled carbon nanotubes. Part Fibre Toxicol 11:3

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  58. Zeidler-Erdely PC, Meighan TG, Erdely A, Battelli LA, Kashon ML, Keane M, Antonini JM (2013) Lung tumor promotion by chromium-containing welding particulate matter in a mouse model. Part Fibre Toxicol 10:45

    Article  PubMed Central  PubMed  Google Scholar 

  59. Witschi H, Malkinson AM, Thompson JA (1989) Metabolism and pulmonary toxicity of butylated hydroxytoluene (BHT). Pharmacol Ther 42(1):89–113

    Article  CAS  PubMed  Google Scholar 

  60. Bauer AK, Dwyer-Nield LD, Hankin JA, Murphy RC, Malkinson AM (2001) The lung tumor promoter, butylated hydroxytoluene (BHT), causes chronic inflammation in promotion-sensitive BALB/cByJ mice but not in promotion-resistant CXB4 mice. Toxicology 169(1):1–15

    Article  CAS  PubMed  Google Scholar 

  61. Bauer AK, Dwyer-Nield LD, Keil K, Koski K, Malkinson AM (2001) Butylated hydroxytoluene (BHT) induction of pulmonary inflammation: a role in tumor promotion. Exp Lung Res 27(3):197–216

    Article  CAS  PubMed  Google Scholar 

  62. Meyer AM, Dwyer-Nield LD, Hurteau GJ, Keith RL, O’Leary E, You M, Bonventre JV, Nemenoff RA, Malkinson AM (2004) Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2. Carcinogenesis 25(8):1517–1524

    Article  CAS  PubMed  Google Scholar 

  63. Vikis HG, Gelman AE, Franklin A, Stein L, Rymaszewski A, Zhu J, Liu P, Tichelaar JW, Krupnick AS, You M (2012) Neutrophils are required for 3-methylcholanthrene-initiated, butylated hydroxytoluene-promoted lung carcinogenesis. Mol Carcinog 51(12):993–1002

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  64. Malkinson AM, Radcliffe RA, Bauer AK (2002) Quantitative trait locus mapping of susceptibilities to butylated hydroxytoluene-induced lung tumor promotion and pulmonary inflammation in CXB mice. Carcinogenesis 23(3):411–417

    Article  CAS  PubMed  Google Scholar 

  65. Chan KH, Yeung SC, Yao TJ, Ip MS, Cheung AH, Chan-Yeung MM, Mak JC, COPD Study Group of the Hong Kong Thoracic Society(2010) Elevated plasma adiponectin levels in patients with chronic obstructive pulmonary disease. Int J Tuberc Lung Dis 14(9):1193–1200

    CAS  PubMed  Google Scholar 

  66. Karabela SP, Psallidas I, Sherrill TP, Kairi CA, Zaynagetdinov R, Cheng DS, Vassiliou S, McMahon F, Gleaves LA, Han W, Stathopoulos I, Zakynthinos SG, Yull FE, Roussos C, Kalomenidis I, Blackwell TS, Stathopoulos GT (2012) Opposing effects of bortezomib-induced nuclear factor-kappaB inhibition on chemical lung carcinogenesis. Carcinogenesis 33(4):859–867

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  67. Moghaddam SJ, Ochoa CE, Sethi S, Dickey BF (2011) Nontypeable Haemophilus influenzae in chronic obstructive pulmonary disease and lung cancer. Int J Chron Obstruct Pulmon Dis 6:113–123

    Article  PubMed Central  PubMed  Google Scholar 

  68. Moghaddam SJ, Li H, Cho SN, Dishop MK, Wistuba II, Ji L, Kurie JM, Dickey BF, Demayo FJ (2009) Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model. Am J Respir Cell Mol Biol 40(4):443–453

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  69. Ochoa CE, Mirabolfathinejad SG, Ruiz VA, Evans SE, Gagea M, Evans CM, Dickey BF, Moghaddam SJ (2011) Interleukin 6, but not T helper 2 cytokines, promotes lung carcinogenesis. Cancer Prev Res (Phila) 4(1):51–64

    Article  CAS  Google Scholar 

  70. Byers TE, Vena JE, Rzepka TF (1984) Predilection of lung cancer for the upper lobes: an epidemiologic inquiry. J Natl Cancer Inst 72(6):1271–1275

    CAS  PubMed  Google Scholar 

  71. Karoor V, Le M, Merrick D, Fagan KA, Dempsey EC, Miller YE (2012) Alveolar hypoxia promotes murine lung tumor growth through a VEGFR-2/EGFR-dependent mechanism. Cancer Prev Res (Phila) 5(8):1061–1071

    Article  CAS  Google Scholar 

  72. Kim WY, Perera S, Zhou B, Carretero J, Yeh JJ, Heathcote SA, Jackson AL, Nikolinakos P, Ospina B, Naumov G, Brandstetter KA, Weigman VJ, Zaghlul S, Hayes DN, Padera RF, Heymach JV, Kung AL, Sharpless NE, Kaelin WG Jr, Wong KK (2009) HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest 119(8):2160–2170

    Google Scholar 

  73. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, Tuveson DA (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15(24):3243–3248

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  74. Ji H, Houghton AM, Mariani TJ, Perera S, Kim CB, Padera R, Tonon G, McNamara K, Marconcini LA, Hezel A, El-Bardeesy N, Bronson RT, Sugarbaker D, Maser RS, Shapiro SD, Wong KK (2006) K-ras activation generates an inflammatory response in lung tumors. Oncogene 25(14):2105–2112

    Article  CAS  PubMed  Google Scholar 

  75. Fukumoto J, Fukumoto I, Parthasarathy PT, Cox R, Huynh B, Ramanathan GK, Venugopal RB, Allen-Gipson DS, Lockey RF, Kolliputi N (2013) NLRP3 deletion protects from hyperoxia-induced acute lung injury. Am J Physiol Cell Physiol 305(2):C182–C189

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  76. Campbell WB, Halushka PV (1996) Lipid-derived autocoids: eicosanoids and platelet-activating factor. In: Hardman JG et al (eds) Goodman and Gilman’s the pharmacological basis of therapeutics. McGraw-Hill, New York, pp 601–616

    Google Scholar 

  77. Smith WL, DeWitt DL, Garavito RM (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69:145–182

    Article  CAS  PubMed  Google Scholar 

  78. Herschman HR (1996) Prostaglandin synthase 2. Biochim Biophys Acta 1299(1):125–140

    Article  PubMed  Google Scholar 

  79. Bauer AK, Dwyer-Nield LD, Malkinson AM (2000) High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors. Carcinogenesis 21(4):543–550

    Article  CAS  PubMed  Google Scholar 

  80. Ermert L, Dierkes C, Ermert M (2003) Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Clin Cancer Res 9(5):1604–1610

    CAS  PubMed  Google Scholar 

  81. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A (1998) Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58(22):4997–5001

    CAS  PubMed  Google Scholar 

  82. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, Takahashi T (1998) Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58(17):3761–3764

    CAS  PubMed  Google Scholar 

  83. Stolfi C, Fina D, Caruso R, Caprioli F, Sarra M, Fantini MC, Rizzo A, Pallone F, Monteleone G (2008) Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol 75(3):668–676

    Article  CAS  PubMed  Google Scholar 

  84. Finetti F, Solito R, Morbidelli L, Giachetti A, Ziche M, Donnini S (2008) Prostaglandin E-2 regulates angiogenesis via activation of fibroblast growth factor receptor-1. J Biol Chem 283(4):2139–2146

    Article  CAS  PubMed  Google Scholar 

  85. Leone V, di Palma A, Ricchi P, Acquaviva F, Giannouli M, Di Prisco AM, Iuliano F, Acquaviva AM (2007) PGE(2) inhibits apoptosis in human adenocarcinoma Caco-2 cell line through Ras-PI3K association and cAMP-dependent kinase A activation. Am J Physiol Gastrointest Liver Physiol 293(4):G673–G681

    Article  CAS  PubMed  Google Scholar 

  86. Rao R, Redha R, Macias-Perez I, Su Y, Hao CM, Zent R, Breyer MD, Pozzi A (2007) Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo. J Biol Chem 282(23):16959–16968

    Article  CAS  PubMed  Google Scholar 

  87. Kamiyama M, Pozzi A, Yang L, DeBusk LM, Breyer RM, Lin PC (2006) EP2, a receptor for PGE(2), regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. Oncogene 25(53):7019–7028

    Article  CAS  PubMed  Google Scholar 

  88. Nishikawa M, Stapleton PP, Freeman TA, Gaughan JP, Matsuda T, Daly JM (2004) NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model. J Am Coll Surg 199(3):428–435

    Article  PubMed  Google Scholar 

  89. Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Levin B, Hawk ET, Cohen DS, Ayers GD, Stephens LC (2004) Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev 13(6):920–927

    CAS  PubMed  Google Scholar 

  90. Fosslien E (2001) Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann Clin Lab Sci 31(4):325–348

    CAS  PubMed  Google Scholar 

  91. Gately S (2000) The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 19(1–2):19–27

    Article  CAS  PubMed  Google Scholar 

  92. Tsujii M, Dubois RN (1995) Alterations in cellular adhesion and apoptosis in epithelial-cells overexpressing prostaglandin-endoperoxide-synthase-2. Cell 83(3):493–501

    Article  CAS  PubMed  Google Scholar 

  93. Honn KV, Meyer J, Neagos G, Henderson T, Westley C, Ratanatharathorn V (1982) Control of tumor growth and metastasis with prostacyclin and thromboxane synthetase inhibitors: evidence for a new antitumor and antimetastatic agent (BAY g 6575). Prog Clin Biol Res 89:295–331

    CAS  PubMed  Google Scholar 

  94. Marcus AJ, Broekman MJ, Pinsky DJ (2002) COX inhibitors and thromboregulation. N Engl J Med 347(13):1025–1026

    Article  PubMed  Google Scholar 

  95. Keith RL, Miller YE, Hoshikawa Y, Moore MD, Gesell TL, Gao B, Malkinson AM, Golpon HA, Nemenoff RA, Geraci MW (2002) Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res 62(3):734–740

    CAS  PubMed  Google Scholar 

  96. Keith RL, Miller YE, Hudish TM, Girod CE, Sotto-Santiago S, Franklin WA, Nemenoff RA, March TH, Nana-Sinkam SP, Geraci MW (2004) Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res 64(16):5897–5904

    Article  CAS  PubMed  Google Scholar 

  97. Nemenoff R, Meyer AM, Hudish TM, Mozer AB, Snee A, Narumiya S, Stearman RS, Winn RA, Weiser-Evans M, Geraci MW, Keith RL (2008) Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor gamma. Cancer Prev Res (Phila) 1(5):349–356

    Article  CAS  Google Scholar 

  98. Keith RL, Geraci MW, Nana-Sinkam SP, Breyer RM, Hudish TM, Meyer AM, Malkinson AM, Dwyer-Nield LD (2006) Prostaglandin E2 receptor subtype 2 (EP2) null mice are protected against murine lung tumorigenesis. Anticancer Res 26(4B):2857–2861

    CAS  PubMed  Google Scholar 

  99. Blaine SA, Meyer AM, Hurteau G, Wick M, Hankin JA, Murphy RC, Dannenberg AJ, Geraci MW, Subbaramaiah K, Nemenoff RA (2005) Targeted over-expression of mPGES-1 and elevated PGE2 production is not sufficient for lung tumorigenesis in mice. Carcinogenesis 26(1):209–217

    Article  CAS  PubMed  Google Scholar 

  100. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J (1997) The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272(30):18779–18789

    Article  CAS  PubMed  Google Scholar 

  101. Li H, Weiser-Evans MC, Nemenoff R (2012) Anti- and protumorigenic effects of PPARgamma in lung cancer progression: a double-edged sword. PPAR Res 2012:362085

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  102. Astapova O, Leff T (2012) Adiponectin and PPARgamma: cooperative and interdependent actions of two key regulators of metabolism. Vitam Horm 90:143–162

    Article  CAS  PubMed  Google Scholar 

  103. Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53:409–435

    Article  CAS  PubMed  Google Scholar 

  104. Chen D, Jin G, Wang Y, Wang H, Liu H, Liu Y, Fan W, Ma H, Miao R, Hu Z, Sun W, Qian J, Jin L, Wei Q, Shen H, Huang W, Lu D (2008) Genetic variants in peroxisome proliferator-activated receptor-gamma gene are associated with risk of lung cancer in a Chinese population. Carcinogenesis 29(2):342–350

    Article  PubMed  CAS  Google Scholar 

  105. Bren-Mattison Y, Van Putten V, Chan D, Winn R, Geraci MW, Nemenoff RA (2005) Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene 24(8):1412–1422

    Article  CAS  PubMed  Google Scholar 

  106. Bren-Mattison Y, Meyer AM, Van Putten V, Li H, Kuhn K, Stearman R, Weiser-Evans M, Winn RA, Heasley LE, Nemenoff RA (2008) Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Mol Pharmacol 73(3):709–717

    Article  CAS  PubMed  Google Scholar 

  107. Li H, Sorenson AL, Poczobutt J, Amin J, Joyal T, Sullivan T, Crossno JT Jr, Weiser-Evans MC, Nemenoff RA (2011) Activation of PPARgamma in myeloid cells promotes lung cancer progression and metastasis. PLoS ONE 6(12):e28133

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  108. Tsao TS, Lodish HF, Fruebis J (2002) ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol 440(2–3):213–221

    Article  CAS  PubMed  Google Scholar 

  109. Carolan BJ, Kim YI, Williams AA, Kechris K, Lutz S, Reisdorph N, Bowler RP (2013) The association of adiponectin with computed tomography phenotypes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 188(5):561–566

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  110. Miller M, Cho JY, Pham A, Ramsdell J, Broide DH (2009) Adiponectin and functional adiponectin receptor 1 are expressed by airway epithelial cells in chronic obstructive pulmonary disease. J Immunol 182(1):684–691

    Article  CAS  PubMed  Google Scholar 

  111. Miller M, Pham A, Cho JY, Rosenthal P, Broide DH (2010) Adiponectin-deficient mice are protected against tobacco-induced inflammation and increased emphysema. Am J Physiol Lung Cell Mol Physiol 299(6):L834–L842

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  112. Sun Y, Lodish HF (2010) Adiponectin deficiency promotes tumor growth in mice by reducing macrophage infiltration. PLoS ONE 5(8):e11987

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  113. Tomoda K, Yoshikawa M, Itoh T, Tamaki S, Fukuoka A, Komeda K, Kimura H (2007) Elevated circulating plasma adiponectin in underweight patients with COPD. Chest 132(1):135–140

    Article  CAS  PubMed  Google Scholar 

  114. Karin M, Cao Y, Greten FR, Li ZW (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2(4):301–310

    Article  CAS  PubMed  Google Scholar 

  115. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118(3):285–296

    Article  CAS  PubMed  Google Scholar 

  116. Maeda S, Kamata H, Luo JL, Leffert H, Karin M (2005) IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121(7):977–990

    Article  CAS  PubMed  Google Scholar 

  117. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431(7007):461–466

    Article  CAS  PubMed  Google Scholar 

  118. Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ, Marinkovich MP, Tao S, Lin Q, Kubo Y, Khavari PA (2003) NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421(6923):639–643

    Article  CAS  PubMed  Google Scholar 

  119. Seitz CS, Lin Q, Deng H, Khavari PA (1998) Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proc Natl Acad Sci U S A 95(5):2307–2312

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  120. van Hogerlinden M, Rozell BL, Ahrlund-Richter L, Toftgard R (1999) Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling. Cancer Res 59(14):3299–3303

    PubMed  Google Scholar 

  121. Sakurai T, Maeda S, Chang L, Karin M (2006) Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci U S A 103(28):10544–10551

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  122. Stathopoulos GT, Sherrill TP, Cheng DS, Scoggins RM, Han W, Polosukhin VV, Connelly L, Yull FE, Fingleton B, Blackwell TS (2007) Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis. Proc Natl Acad Sci U S A 104(47):18514–18519

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  123. Zaynagetdinov R, Stathopoulos GT, Sherrill TP, Cheng DS, McLoed AG, Ausborn JA, Polosukhin VV, Connelly L, Zhou W, Fingleton B, Peebles RS, Prince LS, Yull FE, Blackwell TS (2012) Epithelial nuclear factor-kappaB signaling promotes lung carcinogenesis via recruitment of regulatory T lymphocytes. Oncogene 31(26):3164–3176

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  124. Taylor RC, Acquaah-Mensah G, Singhal M, Malhotra D, Biswal S (2008) Network inference algorithms elucidate Nrf2 regulation of mouse lung oxidative stress. PLoS Comput Biol 4(8):e1000166

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  125. Davies AM, Chansky K, Lara PN Jr, Gumerlock PH, Crowley J, Albain KS, Vogel SJ, Gandara DR, Southwest Oncology G (2009) Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol 4(1):87–92

    Article  PubMed Central  PubMed  Google Scholar 

  126. Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH (2006) Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 24(31):5025–5033

    Article  CAS  PubMed  Google Scholar 

  127. Stathopoulos GT, Sherrill TP, Han W, Sadikot RT, Polosukhin VV, Fingleton B, Yull FE, Blackwell TS (2008) Use of bioluminescent imaging to investigate the role of nuclear factor-kappaBeta in experimental non-small cell lung cancer metastasis. Clin Exp Metastasis 25(1):43–51

    Article  CAS  PubMed  Google Scholar 

  128. Taguchi K, Motohashi H, Yamamoto M (2011) Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 16(2):123–140

    Article  CAS  PubMed  Google Scholar 

  129. Lee JH, Khor TO, Shu L, Su ZY, Fuentes F, Kong AN (2012) Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression. Pharmacol Ther 137:153–171

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  130. Kwak MK, Kensler TW (2010) Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol 244(1):66–76

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  131. Cho HY, Kleeberger SR (2010) Nrf2 protects against airway disorders. Toxicol Appl Pharmacol 244(1):43–56

    Article  CAS  PubMed  Google Scholar 

  132. Sporn MB, Liby KT (2012) NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 12(8):564–571

    Article  CAS  PubMed  Google Scholar 

  133. Rotblat B, Melino G, Knight RA (2012) NRF2 and p53: Januses in cancer? Oncotarget 3(11):1272–1283

    PubMed Central  PubMed  Google Scholar 

  134. Jaiswal AK (2004) Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic Biol Med 36(10):1199–1207

    Article  CAS  PubMed  Google Scholar 

  135. Bobrovnikova-Marjon E, Grigoriadou C, Pytel D, Zhang F, Ye J, Koumenis C, Cavener D, Diehl JA (2010) PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage. Oncogene 29(27):3881–3895

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  136. Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman RJ, Diehl JA (2003) Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol Cell Biol 23(20):7198–7209

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  137. Hayes JD, McMahon M, Chowdhry S, Dinkova-Kostova AT (2010) Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal 13(11):1713–1748

    Article  CAS  PubMed  Google Scholar 

  138. Hu R, Saw CL, Yu R, Kong AN (2010) Regulation of NF-E2-related factor 2 signaling for cancer chemoprevention: antioxidant coupled with antiinflammatory. Antioxid Redox Signal 13(11):1679–1698

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  139. Perera RM, Bardeesy N (2011) Cancer: when antioxidants are bad. Nature 475(7354):43–44

    Article  CAS  PubMed  Google Scholar 

  140. McCarthy N (2011) Tumorigenesis: oncogene detox programme. Nat Rev Cancer 11(9):622–623

    PubMed  Google Scholar 

  141. Cho HY, Imani F, Miller-DeGraff L, Walters D, Melendi GA, Yamamoto M, Polack FP, Kleeberger SR (2009) Antiviral activity of Nrf2 in a murine model of respiratory syncytial virus disease. Am J Respir Crit Care Med 179(2):138–150

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  142. Rangasamy T, Cho CY, Thimmulappa RK, Zhen L, Srisuma SS, Kensler TW, Yamamoto M, Petrache I, Tuder RM, Biswal S (2004) Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest 114(9):1248–1259

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  143. Cho HY, Reddy SP, Debiase A, Yamamoto M, Kleeberger SR (2005) Gene expression profiling of NRF2-mediated protection against oxidative injury. Free Radic Biol Med 38(3):325–343

    Article  CAS  PubMed  Google Scholar 

  144. Iida K, Itoh K, Kumagai Y, Oyasu R, Hattori K, Kawai K, Shimazui T, Akaza H, Yamamoto M (2004) Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res 64(18):6424–6431

    Article  CAS  PubMed  Google Scholar 

  145. Khor TO, Huang MT, Kwon KH, Chan JY, Reddy BS, Kong AN (2006) Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res 66(24):11580–11584

    Article  CAS  PubMed  Google Scholar 

  146. Khor TO, Huang MT, Prawan A, Liu Y, Hao X, Yu S, Cheung WK, Chan JY, Reddy BS, Yang CS, Kong AN (2008) Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer. Cancer Prev Res (Phila) 1(3):187–191

    Article  CAS  Google Scholar 

  147. Xu C, Huang MT, Shen G, Yuan X, Lin W, Khor TO, Conney AH, Kong AN (2006) Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2. Cancer Res 66(16):8293–8296

    Article  CAS  PubMed  Google Scholar 

  148. Bauer AK, Cho HY, Miller-Degraff L, Walker C, Helms K, Fostel J, Yamamoto M, Kleeberger SR (2011) Targeted deletion of Nrf2 reduces urethane-induced lung tumor development in mice. PLoS ONE 6(10):e26590

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  149. Shibutani S, Takeshita M, Grollman AP (1991) Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature 349(6308):431–434

    Article  CAS  PubMed  Google Scholar 

  150. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, Tuveson DA (2011) Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475(7354):106–109

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  151. Satoh H, Moriguchi T, Taguchi K, Takai J, Maher JM, Suzuki T, Winnard PT Jr, Raman V, Ebina M, Nukiwa T, Yamamoto M (2010) Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung. Carcinogenesis 31(10):1833–1843

    Article  CAS  PubMed  Google Scholar 

  152. Mills CD (2001) Macrophage arginine metabolism to ornithine/urea or nitric oxide/citrulline: a life or death issue. Crit Rev Immunol 21(5):399–425

    Article  CAS  PubMed  Google Scholar 

  153. Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7(3):211–217

    Article  CAS  PubMed  Google Scholar 

  154. McCarthy DD, Summers-Deluca L, Vu F, Chiu S, Gao Y, Gommerman JL (2006) The lymphotoxin pathway: beyond lymph node development. Immunol Res 35(1–2):41–54

    Article  CAS  PubMed  Google Scholar 

  155. Tumanov AV, Christiansen PA, Fu YX (2007) The role of lymphotoxin receptor signaling in diseases. Curr Mol Med 7(6):567–578

    Article  CAS  PubMed  Google Scholar 

  156. Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3(9):745–756

    Article  CAS  PubMed  Google Scholar 

  157. Barnes PJ (2000) Mechanisms in COPD: differences from asthma. Chest 117(2 Suppl):10S–14S

    Google Scholar 

  158. Naugler WE, Karin M (2008) The wolf in sheep’s clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 14(3):109–119

    Article  CAS  PubMed  Google Scholar 

  159. O’Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C (2008) Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 223:114–131

    Article  PubMed  Google Scholar 

  160. Loser K, Apelt J, Voskort M, Mohaupt M, Balkow S, Schwarz T, Grabbe S, Beissert S (2007) IL-10 controls ultraviolet-induced carcinogenesis in mice. J Immunol 179(1):365–371

    Article  CAS  PubMed  Google Scholar 

  161. Dercamp C, Chemin K, Caux C, Trinchieri G, Vicari AP (2005) Distinct and overlapping roles of interleukin-10 and CD25 + regulatory T cells in the inhibition of antitumor CD8 T-cell responses. Cancer Res 65(18):8479–8486

    Article  CAS  PubMed  Google Scholar 

  162. Zeni E, Mazzetti L, Miotto D, Lo Cascio N, Maestrelli P, Querzoli P, Pedriali M, De Rosa E, Fabbri LM, Mapp CE, Boschetto P (2007) Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J 30(4):627–632

    Article  CAS  PubMed  Google Scholar 

  163. Bernert H, Sekikawa K, Radcliffe RA, Iraqi F, You M, Malkinson AM (2003) Tnfa and Il-10 deficiencies have contrasting effects on lung tumor susceptibility: gender-dependent modulation of IL-10 haploinsufficiency. Mol Carcinog 38(3):117–123

    Article  CAS  PubMed  Google Scholar 

  164. Kolls JK, Linden A (2004) Interleukin-17 family members and inflammation. Immunity 21(4):467–476

    Article  CAS  PubMed  Google Scholar 

  165. Chang SH, Mirabolfathinejad SG, Katta H, Cumpian AM, Gong L, Caetano MS, Moghaddam SJ, Dong C (2014) T helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci U S A 111(15):5664–5669

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  166. Kleeberger SR, Reddy S, Zhang LY, Jedlicka AE (2000) Genetic susceptibility to ozone-induced lung hyperpermeability: role of toll-like receptor 4. Am J Respir Cell Mol Biol 22(5):620–627

    Article  CAS  PubMed  Google Scholar 

  167. Poltorak A, He X, Smirnova I, Liu MY, Huffel CV, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282(5396):2085–2088

    Article  CAS  PubMed  Google Scholar 

  168. Faure K, Sawa T, Ajayi T, Fujimoto J, Moriyama K, Shime N, Wiener-Kronish JP (2004) TLR4 signaling is essential for survival in acute lung injury induced by virulent Pseudomonas aeruginosa secreting type III secretory toxins. Respir Res 5(1):1

    Article  PubMed Central  PubMed  Google Scholar 

  169. Hollingsworth JW, Whitehead GS, Lin KL, Nakano H, Gunn MD, Schwartz DA, Cook DN (2006) TLR4 signaling attenuates ongoing allergic inflammation. J Immunol 176(10):5856–5862

    Article  CAS  PubMed  Google Scholar 

  170. Zhang X, Shan P, Qureshi S, Homer R, Medzhitov R, Noble PW, Lee PJ (2005) Cutting edge: TLR4 deficiency confers susceptibility to lethal oxidant lung injury. J Immunol 175(8):4834–4838

    Article  CAS  PubMed  Google Scholar 

  171. Higgins SC, Lavelle EC, McCann C, Keogh B, McNeela E, Byrne P, O’Gorman B, Jarnicki A, McGuirk P, Mills KH (2003) Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology. J Immunol 171(6):3119–3127

    Article  CAS  PubMed  Google Scholar 

  172. Hold GL, Rabkin CS, Chow WH, Smith MG, Gammon MD, Risch HA, Vaughan TL, McColl KE, Lissowska J, Zatonski W, Schoenberg JB, Blot WJ, Mowat NA, , Fraumeni JF Jr, El-Omar EM (2007) A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 132(3):905–912

    Google Scholar 

  173. Yusuf N, Nasti TH, Long JA, Naseemuddin M, Lucas AP, Xu H, Elmets CA (2008) Protective role of toll-like receptor 4 during the initiation stage of cutaneous chemical carcinogenesis. Cancer Res 68(2):615–622

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  174. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, Zitvogel L (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13(9):1050–1059

    Article  CAS  PubMed  Google Scholar 

  175. Astrakianakis G, Seixas NS, Ray R, Camp JE, Gao DL, Feng Z, Li W, Wernli KJ, Fitzgibbons ED, Thomas DB, Checkoway H (2007) Lung cancer risk among female textile workers exposed to endotoxin. J Natl Cancer Inst 99(5):357–364

    Article  CAS  PubMed  Google Scholar 

  176. Laakkonen A, Kyyronen P, Kauppinen T, Pukkala EI (2006) Occupational exposure to eight organic dusts and respiratory cancer among Finns. Occup Environ Med 63(11):726–733

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  177. Lange JH, Mastrangelo G, Thomulka KW (2003) Will sewage workers with endotoxin related symptoms have the benefit of reduced lung cancer? Occup Environ Med 60(2):144–145

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  178. Mastrangelo G, Fedeli U, Fadda E, Milan G, Lange JH (2002) Epidemiologic evidence of cancer risk in textile industry workers: a review and update. Toxicol Ind Health 18(4):171–181

    Article  CAS  PubMed  Google Scholar 

  179. Mastrangelo G, Grange JM, Fadda E, Fedeli U, Buja A, Lange JH (2005) Lung cancer risk: effect of dairy farming and the consequence of removing that occupational exposure. Am J Epidemiol 161(11):1037–1046

    Article  PubMed  Google Scholar 

  180. Bauer AK, Dixon D, DeGraff LM, Cho HY, Walker CR, Malkinson AM, Kleeberger SR (2005) Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis. J Natl Cancer Inst 97(23):1778–1781

    Article  CAS  PubMed  Google Scholar 

  181. Heber G, Helbig D, Ponitzsch I, Wetzig T, Harth W, Simon JC (2009) Complete remission of cutaneous and subcutaneous melanoma metastases of the scalp with imiquimod therapy. J Dtsch Dermatol Ges 7(6):534–536

    PubMed  Google Scholar 

  182. Boehm U, Klamp T, Groot M, Howard JC (1997) Cellular responses to interferon-gamma. Annu Rev Immunol 15:749–795

    Article  CAS  PubMed  Google Scholar 

  183. Farrar MA, Schreiber RD (1993) The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 11:571–611

    Article  CAS  PubMed  Google Scholar 

  184. Brandacher G, Winkler C, Schroecksnadel K, Margreiter R, Fuchs D (2006) Antitumoral activity of interferon-gamma involved in impaired immune function in cancer patients. Curr Drug Metab 7(6):599–612

    Article  CAS  PubMed  Google Scholar 

  185. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD (1998) Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 95(13):7556–7561

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  186. Redente EF, Dwyer-Nield LD, Barrett BS, Riches DW, Malkinson AM (2009) Lung tumor growth is stimulated in IFN-gamma−/− mice and inhibited in IL-4Ralpha−/− mice. Anticancer Res 29(12):5095–5101

    CAS  PubMed Central  PubMed  Google Scholar 

  187. Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, Taub DT, Iannettoni MD, Whyte RI, Strieter RM (1996) Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 184(3):981–992

    Article  CAS  PubMed  Google Scholar 

  188. Sharma S, Yang SC, Hillinger S, Zhu LX, Huang M, Batra RK, Lin JF, Burdick MD, Strieter RM, Dubinett SM (2003) SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10. Mol Cancer 2:22

    Article  PubMed Central  PubMed  Google Scholar 

  189. Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA (1998) The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 161(2):927–932

    CAS  PubMed  Google Scholar 

  190. Addison CL, Arenberg DA, Morris SB, Xue YY, Burdick MD, Mulligan MS, Iannettoni MD, Strieter RM (2000) The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Gene Ther 11(2):247–261

    Article  CAS  PubMed  Google Scholar 

  191. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  192. Mantovani A (2012) MSCs, macrophages, and cancer: a dangerous menage-a-trois. Cell Stem Cell 11(6):730–732

    Article  CAS  PubMed  Google Scholar 

  193. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25(12):677–686

    Article  CAS  PubMed  Google Scholar 

  194. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23(11):549–555

    Article  CAS  PubMed  Google Scholar 

  195. Sugiura H, Ichinose M (2011) Nitrative stress in inflammatory lung diseases. Nitric Oxide 25(2):138–144

    Article  CAS  PubMed  Google Scholar 

  196. Albina JE, Reichner JS (2000) Role of macrophag-derived nitric oxide in target cell injury. In: Ignarro IJ (ed) Nitric oxide, biology, and pathobiology. Academic, San Diego, pp 711–724

    Chapter  Google Scholar 

  197. Ischiropoulos H, Thom SR (2000) A comparison of the biological reactivity of nitric oxide and peroxynitrite. In: Ignarro IJ (ed) Nitric oxide, biology, and pathobiology. Academic, San Diego, pp 83–90

    Chapter  Google Scholar 

  198. Liu CY, Wang CH, Chen TC, Lin HC, Yu CT, Kuo HP (1998) Increased level of exhaled nitric oxide and up-regulation of inducible nitric oxide synthase in patients with primary lung cancer. Br J Cancer 78(4):534–541

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  199. Kisley LR, Barrett BS, Bauer AK, Dwyer-Nield LD, Barthel B, Meyer AM, Thompson DC, Malkinson AM (2002) Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis. Cancer Res 62(23):6850–6856

    CAS  PubMed  Google Scholar 

  200. Li QK, Singh A, Biswal S, Askin F, Gabrielson E (2011) KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma. J Hum Genet 56(3):230–234

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  201. Newton R, Seybold J, Kuitert LME, Bergmann M, Barnes PJ (1998) Repression of cyclooxygenase-2 and prostaglandin E-2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA. J Biol Chem 273(48):32312–32321

    Article  CAS  PubMed  Google Scholar 

  202. Ristimaki A, Narko K, Hla T (1996) Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. Biochem J 318:325–331

    CAS  PubMed Central  PubMed  Google Scholar 

  203. Newton R (2000) Molecular mechanisms of glucocorticoid action: what is important? Thorax 55(7):603–613

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  204. Smoak KA, Cidlowski JA (2004) Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev 125(10–11):697–706

    Article  CAS  PubMed  Google Scholar 

  205. Almawi WY, Melemedjian OK (2002) Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J Leukocyte Biol 71(1):9–15

    CAS  PubMed  Google Scholar 

  206. Beato M, Truss M, Chavez S (1996) Control of transcription by steroid hormones. Ann N Y Acad Sci 784:93–123

    Article  CAS  PubMed  Google Scholar 

  207. Jantzen HM, Strahle U, Gloss B, Stewart F, Schmid W, Boshart M, Miksicek R, Schutz G (1987) Cooperativity of glucocorticoid response elements located far upstream of the tyrosine aminotransferase gene. Cell 49(1):29–38

    Article  CAS  PubMed  Google Scholar 

  208. Morrison N, Eisman J (1993) Role of the negative glucocorticoid regulatory element in glucocorticoid repression of the human osteocalcin promoter. J Bone Miner Res 8(8):969–975

    Article  CAS  PubMed  Google Scholar 

  209. Sakai DD, Helms S, Carlstedtduke J, Gustafsson JA, Rottman FM, Yamamoto KR (1988) Hormone-mediated repression—a negative glucocorticoid response element from the bovine prolactin gene. Genes Dev 2(9):1144–1154

    Article  CAS  PubMed  Google Scholar 

  210. Wissink S, van Heerde EC, van der Burg B, van der Saag PT (1998) A dual mechanism mediates repression of NF-kappa B activity by glucocorticoids. Mol Endocrinol 12(3):355–363

    CAS  PubMed  Google Scholar 

  211. Ray A, Prefontaine KE (1994) Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa-B and the glucocorticoid receptor. Proc Natl Acad Sci U S A 91(2):752–756

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  212. Alyaqoub FS, Tao L, Kramer PM, Steele VE, Lubet RA, Gunning WT, Pereira MA (2006) Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (Zarnestra(MT)). Carcinogenesis 27(12):2442–2447

    Article  CAS  PubMed  Google Scholar 

  213. Alyaqoub FS, Tao LH, Kramer PM, Steele VE, Lubet RA, Gunning WT, Pereira MA (2007) Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (Zarnestra(MT)). Carcinogenesis 28(1):124–129

    Article  CAS  PubMed  Google Scholar 

  214. Gunning WT, Kramer PM, Lubet RA, Steele VE, Pereira MA (2000) Chemoprevention of vinyl carbamate-induced lung tumors in strain a mice. Exp Lung Res 26(8):757–772

    Article  CAS  PubMed  Google Scholar 

  215. Lubet RA, Zhang ZQ, Wiseman RW, You M (2000) Use of p53 transgenic mice in the development of cancer models for multiple purposes. Exp Lung Res 26(8):581–593

    Article  CAS  PubMed  Google Scholar 

  216. Oomen LC, van der Valk MA, Hart AA, Demant P (1989) Glucocorticoid hormone effect on transplacental carcinogenesis and lung differentiation: influence of histocompatibility-2 complex. J Natl Cancer Inst 81(7):512–517

    Article  CAS  PubMed  Google Scholar 

  217. Pereira MA, Li YZ, Gunning WT, Kramer PM, Al-Yaqoub F, Lubet RA, Steele VE, Szabo E, Tao LH (2002) Prevention of mouse lung tumors by budesonide and its modulation of biomarkers. Carcinogenesis 23(7):1185–1192

    Article  CAS  PubMed  Google Scholar 

  218. Wattenberg LW, Estensen RD (1996) Chemopreventive effects of myo-inositol and dexamethasone on benzo[a]pyrene and 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone-induced pulmonary carcinogenesis in female A/J mice. Cancer Res 56(22):5132–5135

    CAS  PubMed  Google Scholar 

  219. Witschi H, Espiritu I, Ly M, Uyeminami D (2005) The chemopreventive effects of orally administered dexamethasone in Strain A/J mice following cessation of smoke exposure. Inhalation Toxicol 17(2):119–122

    Article  CAS  Google Scholar 

  220. Witschi H, Espiritu I, Uyeminami D (1999) Chemoprevention of tobacco smoke-induced lung tumors in A/J strain mice with dietary myo-inositol and dexamethasone. Carcinogenesis 20(7):1375–1378

    Article  CAS  PubMed  Google Scholar 

  221. Yao RS, Wang Y, Lemon WJ, Lubet RA, You M (2004) Budesonide exerts its chemopreventive efficacy during mouse lung tumorigenesis by modulating gene expressions. Oncogene 23(46):7746–7752

    Article  CAS  PubMed  Google Scholar 

  222. Wattenberg LW, Wiedmann TS, Estensen RD, Zimmerman CL, Galbraith AR, Steele VE, Kelloff GJ (2000) Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis 21(2):179–182

    Article  CAS  PubMed  Google Scholar 

  223. Wattenberg LW, Estensen RD (1997) Studies of chemopreventive effects of budenoside on benzo[a]pyrene-induced neoplasia of the lung of female A/J mice. Carcinogenesis 18(10):2015–2017

    Article  CAS  PubMed  Google Scholar 

  224. Petersen OH, Michalak M, Verkhratsky A (2005) Calcium signalling: past, present and future. Cell Calcium 38(3–4):161–169

    Article  CAS  PubMed  Google Scholar 

  225. Malkinson AM (2005) Role of inflammation in mouse lung tumorigenesis: a review. Exp Lung Res 31(1):57–82

    Article  CAS  PubMed  Google Scholar 

  226. Cole TJ, Blendy JA, Monaghan AP, Krieglstein K, Schmid W, Aguzzi A, Fantuzzi G, Hummler E, Unsicker K, Schutz G (1995) Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell-development and severely retards lung maturation. Genes Dev 9(13):1608–1621

    Article  CAS  PubMed  Google Scholar 

  227. Droms KA, Malkinson AM (1991) Mechanisms of glucocorticoid involvement in mouse lung tumorigenesis. Exp Lung Res 17(2):359–370

    Article  CAS  PubMed  Google Scholar 

  228. Parimon T, Chien JW, Bryson CL, McDonell MB, Udris EM, Au DH (2007) Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175(7):712–719

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  229. Adriaenssens PI, Sivarajah K, Boorman GA, Eling TE, Anderson MW (1983) Effect of aspirin and indomethacin on the formation of benzo(a)pyrene-induced pulmonary adenomas and DNA adducts in A/Hej mice. Cancer Res 43(10):4762–4767

    CAS  PubMed  Google Scholar 

  230. Duperron C, Castonguay A (1997) Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis 18(5):1001–1006

    Article  CAS  PubMed  Google Scholar 

  231. Jalbert G, Castonguay A (1992) Effects of Nsaids on Nnk-Induced Pulmonary and Gastric Tumorigenesis in a/J Mice. Cancer Lett 66(1):21–28

    Article  CAS  PubMed  Google Scholar 

  232. Kisley LR (2002) Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice. Carcinogenesis 23(10):1653–1660

    Article  CAS  PubMed  Google Scholar 

  233. Moody TW, Leyton J, Zakowicz H, Hida T, Kang Y, Jakowlew S, You L, Ozbun L, Zia H, Youngberg J, Malkinson A (2001) Indomethacin reduces lung adenoma number in A/J mice. Anticancer Res 21(3B):1749–1755

    CAS  PubMed  Google Scholar 

  234. Pepin P, Bouchard L, Nicole P, Castonguay A (1992) Effects of sulindac and oltipraz on the tumorigenicity of 4-(methylnitrosamino)1-(3-Pyridyl)-1-butanone in A/J mouse lung. Carcinogenesis 13(3):341–348

    Article  CAS  PubMed  Google Scholar 

  235. Rioux N, Castonguay A (1998) Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res 58(23):5354–5360

    CAS  PubMed  Google Scholar 

  236. Malkinson AM, Koski KM, Dwyer-Nield LD, Rice PL, Rioux N, Castonguay A, Ahnen DJ, Thompson H, Pamukcu R, Piazza GA (1998) Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumor formation by FGN-1 (sulindac sulfone). Carcinogenesis 19(8):1353–1356

    Article  CAS  PubMed  Google Scholar 

  237. Castonguay A, Rioux N, Duperron C, Jalbert G (1998) Inhibition of lung tumorigenesis by NSAIDS: A working hypothesis. Exp Lung Res 24(4):605–615

    Article  CAS  PubMed  Google Scholar 

  238. Kisley LR, Barrett BS, Dwyer-Nield LD, Bauer AK, Thompson DC, Malkinson AM (2002) Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice. Carcinogenesis 23(10):1653–1660

    Article  CAS  PubMed  Google Scholar 

  239. Montuschi P, Macagno F, Parente P, Valente S, Lauriola L, Ciappi G, Kharitonov SA, Barnes PJ, Ciabattoni G (2005) Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD. Thorax 60(10):827–833

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  240. Avis IM, Jett M, Boyle T, Vos MD, Moody T, Treston AM, Martinez A, Mulshine JL (1996) Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest 97(3):806–813

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  241. Moody TW, Leyton J, Martinez A, Hong S, Malkinson A, Mulshine JL (1998) Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. Exp Lung Res 24(4):617–628

    Article  CAS  PubMed  Google Scholar 

  242. Castonguay A (1998) Inhibition of lung tumorigenesis by NSAIDS: a working hypothesis. Exp Lung Res 24(4):605–615

    Article  CAS  PubMed  Google Scholar 

  243. Gunning WT, Kramer PM, Steele VE, Pereira MA (2002) Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer Res 62(15):4199–4201

    CAS  PubMed  Google Scholar 

  244. Myrdal PB, Karlage K, Kuehl PJ, Angersbach BS, Merrill BA, Wightman D (2007) Effects of novel 5-lipoxygenase inhibitors on the incidence of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation. Carcinogenesis 28(5):957–961

    Article  CAS  PubMed  Google Scholar 

  245. Peters-Golden M, Henderson WR (2007) Mechanisms of disease: leukotrienes. N Engl J Med 357(18):1841–1854

    Article  CAS  PubMed  Google Scholar 

  246. Keith RL, Blatchford PJ, Kittelson J, Minna JD, Kelly K, Massion PP, Franklin WA, Mao J, Wilson DO, Merrick DT, Hirsch FR, Kennedy TC, Bunn PA Jr, Geraci MW, Miller YE (2011) Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res (Phila) 4(6):793–802

    Article  CAS  Google Scholar 

  247. Stumvoll M, Haring HU (2002) Glitazones: clinical effects and molecular mechanisms. Ann Med 34(3):217–224

    Article  CAS  PubMed  Google Scholar 

  248. Wick M, Hurteau G, Dessev C, Chan D, Geraci MW, Winn RA, Heasley LE, Nemenoff RA (2002) Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol 62(5):1207–1214

    Article  CAS  PubMed  Google Scholar 

  249. Keshamouni VG, Reddy RC, Arenberg DA, Joel B, Thannickal VJ, Kalemkerian GP, Standiford TJ (2004) Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 23(1):100–108

    Article  CAS  PubMed  Google Scholar 

  250. Lee SY, Hur GY, Jung KH, Jung HC, Lee SY, Kim JH, Shin C, Shim JJ, In KH, Kang KH, Yoo SH (2006) PPAR-gamma agonist increase gefitinib’s antitumor activity through PTEN expression. Lung Cancer 51(3):297–301

    Article  PubMed  Google Scholar 

  251. Tang JM, He QY, Guo RX, Chang XJ (2006) Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51(2):181–191

    Article  PubMed  Google Scholar 

  252. Lyon CM, Klinge DM, Do KC, Grimes MJ, Thomas CL, Damiani LA, March TH, Stidley CA, Belinsky SA (2009) Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model. Carcinogenesis 30(12):2095–2099

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  253. Wang Y, James M, Wen W, Lu Y, Szabo E, Lubet RA, You M (2010) Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in mice. Mol Cancer Ther 9(11):3074–3082

    Article  CAS  PubMed  Google Scholar 

  254. Brownstein JS, Sordo M, Kohane IS, Mandl KD (2007) The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction. PLoS ONE 2(9):e840

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  255. Yu Y, Ricciotti E, Scalia R, Tang SY, Grant G, Yu Z, Landesberg G, Crichton I, Wu W, Pure E, Funk CD, FitzGerald GA (2012) Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med 4(132):132ra54

    Article  PubMed  Google Scholar 

  256. Keith RL, Miller YE (2013) Lung cancer chemoprevention: current status and future prospects. Nat Rev Clin Oncol 10(6):334–343

    Article  CAS  PubMed  Google Scholar 

  257. (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 330(15):1029–1035

    Google Scholar 

  258. Kamangar F, Qiao YL, Yu B, Sun XD, Abnet CC, Fan JH, Mark SD, Zhao P, Dawsey SM, Taylor PR (2006) Lung cancer chemoprevention: a randomized, double-blind trial in Linxian, China. Cancer Epidemiol Biomarkers Prev 15(8):1562–1564

    Article  CAS  PubMed  Google Scholar 

  259. Karp DD, Lee SJ, Keller SM, Wright GS, Aisner S, Belinsky SA, Johnson DH, Johnston MR, Goodman G, Clamon G, Okawara G, Marks R, Frechette E, McCaskill-Stevens W, Lippman SM, Ruckdeschel J, Khuri FR (2013) Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J Clin Oncol 31(33):4179–4187

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  260. Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, Khuri FR, Marks R, Winn RJ, Fry W, Graziano SL, Gandara DR, Okawara G, Woodhouse CL, Williams B, Perez C, Kim HW, Lotan R, Roth JA, Hong WK (2001) Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 93(8):605–618

    Article  CAS  PubMed  Google Scholar 

  261. van Zandwijk N, Dalesio O, Pastorino U, de Vries N, van Tinteren H (2000) EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 92(12):977–986

    Article  PubMed  Google Scholar 

  262. Kelly RJ, Lopez-Chavez A, Szabo E (2011) Criteria of evidence to move potential chemopreventive agents into late phase clinical trials. Curr Drug Targets 12(13):1983–1988

    Article  CAS  PubMed  Google Scholar 

  263. Prentice RL (1989) Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8(4):431–440

    Article  CAS  PubMed  Google Scholar 

  264. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK (2000) Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320(7245):1297–1303

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  265. Lam S, leRiche JC, McWilliams A, Macaulay C, Dyachkova Y, Szabo E, Mayo J, Schellenberg R, Coldman A, Hawk E, Gazdar A (2004) A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res 10(19):6502–6511

    Article  CAS  PubMed  Google Scholar 

  266. van den Berg RM, Teertstra HJ, van Zandwijk N, van Tinteren H, Visser C, Pasic A, Sutedja TG, Baas P, Golding RP, Postmus PE, Smit EF (2008) CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasone. Lung Cancer 60(1):57–61

    Article  PubMed  Google Scholar 

  267. Veronesi G, Szabo E, Decensi A, Guerrieri-Gonzaga A, Bellomi M, Radice D, Ferretti S, Pelosi G, Lazzeroni M, Serrano D, Lippman SM, Spaggiari L, Nardi-Pantoli A, Harari S, Varricchio C, Bonanni B (2011) Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules. Cancer Prev Res (Phila) 4(1):34–42

    Article  CAS  Google Scholar 

  268. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K (1999) Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 353(9167):1819–1823

    Article  CAS  PubMed  Google Scholar 

  269. Lung Health Study Research Group (2000) Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 343(26):1902–1909

    Article  Google Scholar 

  270. Miller YE, Keith RL (2007) Inhaled corticosteroids and lung cancer chemoprevention. Am J Respir Crit Care Med 175(7):636–637

    Article  CAS  PubMed  Google Scholar 

  271. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294(1):47–55

    Article  CAS  PubMed  Google Scholar 

  272. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377(9759):31–41

    Article  CAS  PubMed  Google Scholar 

  273. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z (2012) Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379(9826):1591–1601

    Article  CAS  PubMed  Google Scholar 

  274. Kim ES, Hong WK, Lee JJ, Mao L, Morice RC, Liu DD, Jimenez CA, Eapen GA, Lotan R, Tang X, Newman RA, Wistuba II, Kurie JM (2010) Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila) 3(2):148–159

    Article  CAS  Google Scholar 

  275. Mao JT, Fishbein MC, Adams B, Roth MD, Goodglick L, Hong L, Burdick M, Strieter ER, Holmes C, Tashkin DP, Dubinett SM (2006) Celecoxib decreases Ki-67 proliferative index in active smokers. Clin Cancer Res 12(1):314–320

    Article  CAS  PubMed  Google Scholar 

  276. Gupta, RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK, DuBois RN (2000) Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A 97(24):13275–13280

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  277. Nakachi I, Rice JL, Coldren CD, Edwards MG, Stearman RS, Glidewell SC, Varella-Garcia M, Franklin WA, Keith RL, Lewis MT, Gao B, Merrick DT, Miller YE, Geraci MW (2014) Application of SNP microarrays to the genome-wide analysis of chromosomal instability in premalignant airway lesions. Cancer Prev Res (Phila) 7(2):255–265

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Environmental and Occupational Health, University of Colorado Denver Anschutz Medical Campus, 12850 E. Montview Blvd Room V20-3125 Aurora, 80045, Aurora, CO, USA

    Asst. Prof. Alison K. Bauer PhD

  2. Division of Pulmonary Sciences and Critical Care Medicine, Denver Veterans Affairs Medical Center, University of Colorado Denver, 1055 Clermont St. Box 111A Denver, 80220, Denver, CO, USA

    Prof. York E. Miller MD

  3. Denver Veterans Affairs Medical Center, University of Colorado Denver, 1055 Clermont St. Box 151 Denver, 80220, Denver, CO, USA

    Prof. Robert L. Keith MD

Authors
  1. Asst. Prof. Alison K. Bauer PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. York E. Miller MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Robert L. Keith MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert L. Keith MD .

Editor information

Editors and Affiliations

  1. David Geffen School of Medicine at UCLA, Los Angeles, California, USA

    Steven M. Dubinett

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Bauer, A., Miller, Y., Keith, R. (2015). Inflammation and Lung Cancer: Prevention. In: Dubinett, S. (eds) Inflammation and Lung Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2724-1_4

Download citation

Publish with us

Policies and ethics

Search

Navigation